N@N

SANTA CLARA, Calif.--([ BUSINESS WIRE ])--XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the Leerink Swann Global Healthcare Conference. The live presentation will occur at 10:30 a.m. Pacific Time (1:30 p.m. Eastern Time) on Thursday, February 16, 2012. A replay of the presentation will also be available.

To access the live presentation via the Web, please go to [ www.XenoPort.com ]. Please connect to the Website at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the Webcast.

A replay of the Webcast can be accessed for a minimum of one week and will be available approximately 24 hours after the live presentation.

About XenoPort

XenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant (gabapentin enacarbil) Extended-Release Tablets is XenoPortas first Food and Drug Administration-approved product. GlaxoSmithKline holds commercialization rights and certain development rights for gabapentin enacarbil in the United States. Regnite (gabapentin enacarbil) is approved for the treatment of moderate-to-severe primary restless legs syndrome in Japan. Astellas Pharma Inc. holds all development and commercialization rights for Regnite in Japan and five Asian countries. XenoPort holds all other world-wide rights and has co-promotion and certain development rights to gabapentin enacarbil in the United States. XenoPortas pipeline of product candidates includes potential treatments for patients with neuropathic pain, spasticity and Parkinsonas disease.

To learn more about XenoPort, please visit the Website at [ www.XenoPort.com ].

XENOPORT is a registered trademark of XenoPort, Inc.

Horizant is a registered trademark of GlaxoSmithKline.

Regnite is a registered trademark of Astellas Pharma Inc.

XNPT2G